CRBP - Latest News
Corbus Pharmaceuticals Holdings, Inc. (CRBP), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $186.9M. Beta to the broader market is 2.62.
The article list below shows the most recent CRBP headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CRBP Headlines
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
globenewswire.com - Aug 4, 2026
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demon
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
globenewswire.com - Jul 28, 2026
Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L set
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
globenewswire.com - Jul 6, 2026
NORWOOD, Mass. , July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
marketbeat.com - Jun 9, 2026
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Yuval Cohen outlined the company's near-term clinical readout schedule and development plans for i
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
seekingalpha.com - Jun 1, 2026
Corbus Pharmaceuticals Holdings, Inc.
How News Affects CRBP Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CRBP's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CRBP news questions
- What is the latest CRBP news headline?
- The most recent CRBP headline (Aug 4, 2026) is "Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CRBP news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CRBP news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CRBP options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.